terbutaline
Trade name: bricanyl
Approved
Mar 25, 1974
Terbutaline is a relatively selective beta2-adrenergic bronchodilator that has little or no effect on alpha-adrenergic receptors. The drug has exerts a preferential effect on beta2-adrenergic receptors but stimulates beta-adrenergic receptors less selectively than relatively selective beta2-agonists. Terbutaline appears to have a greater stimulating effect on beta-receptors of the bronchial, vascular, and uterine smooth muscles (beta2 receptors) than on the beta-receptors of the heart (beta1 receptors). This drug relaxes smooth muscle and inhibits uterine contractions, but may also cause some cardiostimulatory effects and CNS stimulation. The pharmacologic effects of terbutaline are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic- 3',5'- adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Terbutaline is used for the prevention and reversal of bronchospasm in patients 12 years of age and older with reversible, obstructive airway disease, as well as symptomatic management of reversible bronchospasm associated with bronchitis and emphysema. Also used acute IV and sub-Q therapy in selected women to inhibit uterine contractions in preterm labor (tocolysis) and prolong gestation when beneficial. — NCATS
Clinical trial activity
40 trials · 33 clinical orgs · 17 marketing orgs
Earliest trial started Sep 1, 2002 (NCT00802230)
Timeline
1970s
- Mar 25, 1974
Sanofi-Aventis — Earliest FDA Approval
- Mar 25, 1974
Sanofi-Aventis — NDA Secondary Org
- Mar 25, 1974
Sanofi-Aventis — NDA Organization
- May 17, 1976
Ani Pharmaceuticals — NDA Secondary Org
- May 17, 1976
Ani Pharmaceuticals — Marketing Organization
1980s
- Nov 30, 1981
Pharmacare PLC, Palestine — NDA Secondary Org
2000s
- Jun 26, 2001
Impax Laboratories — Marketing Organization
- Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
- Apr 23, 2004
Athenex, Inc. — Marketing Organization
- Apr 23, 2004
Chartwell Pharmaceuticals — Marketing Organization
- May 26, 2004
Fresenius — Marketing Organization
- Jul 20, 2004
Teva — Marketing Organization
- Jul 20, 2004
Dr. Reddy's Laboratories — Marketing Organization
- Mar 25, 2005
Lannett Company, Inc. — Marketing Organization
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
- Jan 7, 2008
Akorn, Inc. — Marketing Organization
- Jan 7, 2008
Epic Pharma Llc — Marketing Organization
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
- May 20, 2009
Hikma — Marketing Organization
2010s
- Nov 8, 2013
United Biomedical — Marketing Organization
- Nov 8, 2013
Areva Med LLC — Marketing Organization
2020s
- Jun 19, 2020
TWi Biotechnology, Inc. — Marketing Organization
Indications
Approved for
Studied for
- Asthma · Phase 4
- Asthma, Exercise-Induced · Phase 2
- Diabetes Mellitus, Type 1 · Phase 1
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 4
- Labor Pain · Phase 4
- Pain · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Purpura, Thrombocytopenic, Idiopathic · Phase 2
- Status Asthmaticus · Phase 4
- Version, Fetal · Phase 4
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Approval history
- approvedPriority reviewMar 25, 1974
Chemistry & pharmacology
SMILES
CC(C)(C)NCC(O)c1cc(O)cc(O)c1.CC(C)(C)NCC(O)c1cc(O)cc(O)c1.O=S(=O)(O)O- Mol. weight
- 548.66 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL1315867 ↗
- WikipediaTerbutaline ↗
- NCATSN8ONU3L3PG ↗
- ChEMBLCHEMBL1760 ↗
- ChEMBLCHEMBL1160544 ↗
Also known as
- brethaire
- brethaire
- brethine
- brethine
- brican
- bricanyl
- bricanyl
- bricanyl
- bricanyl
- bricanyl sa
- bricanyl sa
- bricaril
- kwd-2019
- kwd-2019
- monovent
- monovent
- monovent sa
- terbasmin
- terbasmin
- terbutalin
- terbutalin
- terbutalin
- terbutalin
- terbutalina
- terbutalina
- terbutaline
- terbutaline
- terbutaline
- terbutaline
- terbutaline
- terbutaline
- terbutaline
- terbutaline
- terbutaline
- terbutaline
- terbutaline hemisulfate
- terbutaline hemisulfate
- terbutaline sulfate
- terbutaline sulfate
- terbutaline sulfate
- terbutaline sulfate
- terbutaline (sulfate de)
- terbutaline (sulfate de)
- terbutaline sulphate
- terbutaline sulphate
- terbutaline sulphate
- terbutalini sulfas
- terbutalini sulfas
- terbutalinsulfat
- terbutalinum
- terbutalinum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06626620 | Phase 3 | Jan 1, 2024 | Nishtar Medical University, RESnTEC, Institute of Research |
| NCT05494307 | Phase 2 | Sep 1, 2022 | Peking University |
| NCT04973345 | Phase 2/Phase 3 (Phase 3) | Mar 31, 2022 | Duke University, The EMMES Corporation |
| NCT05193968 | N/A | Feb 24, 2022 | Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
| NCT04705727 | Phase 3 | Apr 12, 2021 | AstraZeneca, Centre Hospitalier Intercommunal Creteil |
| NCT04481282 | Phase 2 | Jul 8, 2020 | Peking University |
| NCT03565302 | N/A | Jun 25, 2018 | University of Copenhagen |
| NCT05326269 | N/A | Apr 23, 2017 | Hospital Kemaman |
| NCT03106753 | Phase 4 | Apr 12, 2017 | Icahn School of Medicine at Mount Sinai |
| NCT04468568 | N/A | Jan 8, 2017 | University of Sao Paulo |
| NCT02712658 | N/A | Sep 1, 2015 | University of Copenhagen |
| NCT02557581 | N/A | Jul 1, 2015 | University of Copenhagen |
| NCT02322788 | Phase 3 | Mar 1, 2015 | AstraZeneca |
| NCT02224157 | Phase 3 | Nov 28, 2014 | AstraZeneca |
| NCT02178059 | Phase 1 | Aug 1, 2014 | AstraZeneca, IQVIA |
| NCT02149199 | Phase 3 | Jul 7, 2014 | AstraZeneca |
| NCT02115256 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2014 | Icahn School of Medicine at Mount Sinai |
| NCT01944033 | Phase 3 | Jul 1, 2013 | University of Monastir |
| NCT01651962 | Phase 4 | Aug 1, 2012 | University of Arizona |
| NCT02103374 | Phase 4 | Jan 1, 2012 | University of Toulouse |
Organizations
Research & Development (33)
Marketing (19)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | MKTG | Jan 7, 2008 |
| Ani Pharmaceuticals | For profit | NDA2 | May 17, 1976 |
| Ani Pharmaceuticals | For profit | MKTG | May 17, 1976 |
| Areva Med LLC | For profit | MKTG | Nov 8, 2013 |
| Athenex, Inc. | For profit | MKTG | Apr 23, 2004 |
| Chartwell Pharmaceuticals | For profit | MKTG | Apr 23, 2004 |
| Dr. Reddy's Laboratories | For profit | MKTG | Jul 20, 2004 |
| Epic Pharma Llc | For profit | MKTG | Jan 7, 2008 |
| Fresenius | For profit | MKTG | May 26, 2004 |
| Hikma | For profit | MKTG | May 20, 2009 |
| Impax Laboratories | For profit | MKTG | Jun 26, 2001 |
| Lannett Company, Inc. | For profit | MKTG | Mar 25, 2005 |
| Novartis | For profit | NDA2 | — |
| Pharmacare PLC, Palestine | For profit | NDA2 | Nov 30, 1981 |
| Sanofi-Aventis | For profit | NDA2 | Mar 25, 1974 |
| Sanofi-Aventis | For profit | NDA | Mar 25, 1974 |
| TWi Biotechnology, Inc. | For profit | MKTG | Jun 19, 2020 |
| Teva | For profit | MKTG | Jul 20, 2004 |
| United Biomedical | For profit | MKTG | Nov 8, 2013 |